Request for Proposals (RFP)
Independent Medical Education Grants
Progress in Androgen Deprivation Therapy (ADT) in Advanced Prostate Cancer
Competitive Grant Program - internal company review process

I. Background
Pfizer Global Medical Grants (GMG) and Myovant Sciences support the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with our joint medical and/or scientific strategies.

Pfizer GMG and Myovant Sciences’ aligned competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer / Myovant must not be involved in any aspect of project development, nor the conduct of the independent education program.

II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>United States</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Applicant Eligibility Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.</td>
</tr>
<tr>
<td>• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.</td>
</tr>
<tr>
<td>• For projects offering continuing education credit, the requesting organization must be accredited.</td>
</tr>
</tbody>
</table>
# III. Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued:</th>
<th>May 6, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area:</td>
<td>Prostate Cancer</td>
</tr>
</tbody>
</table>
| Specific Area of Interest for this RFP: | The general Area of Interest and goals of the medical education:  
- Raise awareness of cardiovascular risk in patients with prostate cancer receiving Androgen Deprivation Treatment (ADT)  
- Differentiate the clinical significance of LHRH agonists vs. GnRH antagonists  
- Provide multidisciplinary care teams the latest updates on ADT treatment options  
- Mindfully recognize patient preference and adherence data regarding oral vs. parenteral oncologic therapy  

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.  
Proposals for independent medical education programs may include:  
- All activity formats including live in-person, live virtual, enduring virtual, print materials, innovative communication channels, apps, social media, digital programs, and resources or tools for clinical practice.  
- Novel decision-making tools for healthcare professions to use with their patients to support informed patient decision making and drive patient engagement in their care. |
| Target Audience | Urologists, Medical Oncologists, Radio-Oncologists, allied Prostate Cancer healthcare providers |
| Expected Approximate Monetary Range of Grant Applications: | Expected Approximate Monetary Range of Grant Applications:  
Individual projects requesting up to $250,000 will be considered.  
The estimated total available budget related to this RFP is $2,000,000 USD |
| Key Dates: | RFP release date: **May 6, 2021**  
Grant Application due date: **June 30, 2021**  
Please note the deadline is 23:59 Eastern Standard Time  
Anticipated Grant Award Notification Date: **July 26, 2021**  
Grants will be distributed following a fully executed agreement.  
Anticipated Approx. Project Start and End Dates: **August 2021 – August 2022**  
(1 year to 18 months project length is preferred, maximum project length is 2 years) |
### How to Submit:

Please go to [www.cybergrants.com/pfizer/knowledge](http://www.cybergrants.com/pfizer/knowledge) and sign in. First-time users should click “Create your password”.

In the application:
- For the question “What type of request are you submitting?” select **Response to a Request for Proposal (RFP)**
- For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select **Yes**
- Select the following Competitive Grant Program Name: **2021 Oncology: Progress in ADT in Advanced Prostate Cancer**
- Select the following Primary Area of Interest: **Oncology – Genitourinary - Prostate**

Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.

If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed by the committee.

### Questions:

If you have questions regarding this RFP, please direct them in writing to Dewayne Brumlow at [Dewayne.Brumlow@pfizer.com](mailto:Dewayne.Brumlow@pfizer.com), with the subject line “Progress in Androgen Deprivation Therapy (ADT) in Advanced Prostate Cancer”

### Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](http://www.cybergrants.com/pfizer/knowledge) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.

### Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer and Myovant Sciences to make final grant decisions.

### Mechanism by which Applicants will be Notified:

All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification during the review period.
Appendix - General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

| Goals and Objectives | • Briefly state the overall goal of the project.  
<p>|                       | • List the objectives you plan to meet with your project, in terms of learning and expected outcomes. |
| Needs Assessment for the Project | • Include a description of your organization’s needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. |
| Target Audience | • Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population. |
| Project Design and Methods | • Describe the planned project, the educational approach, and the way the planned methods address the established need. |
| Innovation | • Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions. |
| Evaluation and Outcomes | • In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project. |
| Dissemination Plan | • Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated. |
| Anticipated Project Timeline | • Provide an anticipated timeline for your project including project start/end dates. |</p>
<table>
<thead>
<tr>
<th>Additional Information</th>
<th>If there is any additional information you feel the Global Strategic Alliance should be aware of concerning the importance of this project, please summarize here.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organization Detail</td>
<td>Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.</td>
</tr>
</tbody>
</table>
| Budget Narrative       | Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.  
|                        | While estimating your budget please keep the following items in mind:  
|                        | o Independent Medical Education Grants awarded by the Global Strategic Alliance cannot be used to purchase therapeutic assets (prescription or non-prescription).  
|                        | o Overhead rates of more than 28% of the total proposed project budget will not be supported. |